

Review: Chemotherapy-induced diarrhea: pathophysiology and management

Therapeutic Advances in Medical Oncology

2, 51-63

DOI: [10.1177/1758834009355164](https://doi.org/10.1177/1758834009355164)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. <i>Science</i> , 2010, 330, 831-835.	6.0	800
2	Potential Repurposing of Known Drugs as Potent Bacterial β -Glucuronidase Inhibitors. <i>Journal of Biomolecular Screening</i> , 2012, 17, 957-965.	2.6	35
4	Nosocomial Diarrhea: Evaluation and Treatment of Causes Other Than <i>Clostridium difficile</i> . <i>Clinical Infectious Diseases</i> , 2012, 55, 982-989.	2.9	140
5	New Frontiers in Mucositis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 545-551.	1.8	21
6	Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. <i>Supportive Care in Cancer</i> , 2013, 21, 2341-2349.	1.0	44
7	Developing a metagenomic view of xenobiotic metabolism. <i>Pharmacological Research</i> , 2013, 69, 21-31.	3.1	159
8	Effets indésirables des médicaments anticancéreux utilisés en pneumologie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 367-374.	0.0	0
9	Association Between Ipilimumab and Celiac Disease. <i>Mayo Clinic Proceedings</i> , 2013, 88, 414-417.	1.4	58
10	Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. <i>Pharmaceuticals</i> , 2013, 6, 988-1038.	1.7	16
11	Identifying Strategies to Optimize Care With Oral Cancer Therapy. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 629-636.	0.3	11
12	Adherence Issues for Oral Antineoplastics. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 206-222.	0.8	1
13	Resolution of <i>Clostridium difficile</i> "Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. <i>Journal of Clinical Oncology</i> , 2013, 31, 2493-2499.	0.8	93
14	Molecular Insights into Microbial β -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity. <i>Molecular Pharmacology</i> , 2013, 84, 208-217.	1.0	105
15	Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report. <i>Journal of Korean Medical Science</i> , 2013, 28, 1549.	1.1	4
16	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. <i>Cancer Management and Research</i> , 2014, 6, 93.	0.9	18
17	Management of locally advanced and metastatic colon cancer in elderly patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 1910.	1.4	17
18	Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. <i>Cell Death and Disease</i> , 2014, 5, e1454-e1454.	2.7	43
19	Complications of systemic therapy " gut infections and acute diarrhoea. <i>Clinical Medicine</i> , 2014, 14, 528-531.	0.8	2

#	ARTICLE	IF	CITATIONS
20	Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. <i>Annals of Oncology</i> , 2014, 25, 455-461.	0.6	33
21	Adverse Event Management Strategies. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, E19-E25.	0.3	5
22	Ipilimumab-induced colitis: a rare but serious side effect. <i>Endoscopy</i> , 2014, 46, E308-E309.	1.0	10
23	EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells. <i>Life Sciences</i> , 2014, 119, 28-33.	2.0	17
24	Irinophore C ₆₀ , a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. <i>Investigational New Drugs</i> , 2014, 32, 1071-1082.	1.2	14
25	IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21WAF1 and p27KIP1. <i>Pharmacological Research</i> , 2014, 82, 21-33.	3.1	19
27	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	2.0	47
28	IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. <i>Mucosal Immunology</i> , 2014, 7, 1079-1093.	2.7	73
29	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 675-680.	1.1	28
31	Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats. <i>Medical Molecular Morphology</i> , 2014, 47, 100-107.	0.4	98
32	Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 559-580.	4.2	37
33	Protocolo diagnóstico y terapéutico de la diarrea aguda en el entorno hospitalario. <i>Medicine</i> , 2014, 11, 3304-3308.	0.0	1
34	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 509-520.	1.1	46
35	Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. <i>Oncotarget</i> , 2015, 6, 22496-22512.	0.8	303
36	Discovery of Specific Inhibitors for Intestinal <i>E. coli</i> Î²-Glucuronidase through In Silico Virtual Screening. <i>Scientific World Journal</i> , The, 2015, 2015, 1-8.	0.8	10
38	Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea. <i>Journal of Biological Chemistry</i> , 2015, 290, 11246-11257.	1.6	32
39	Les inhibiteurs de tyrosine kinase. <i>Actualites Pharmaceutiques</i> , 2015, 54, 22-27.	0.0	0
40	Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. <i>Annals of Oncology</i> , 2015, 26, 992-997.	0.6	101

#	ARTICLE	IF	CITATIONS
41	Regorafenib: start low and go slow. Targeted Oncology, 2015, 10, 445-447.	1.7	20
42	Risk factors associated with Clostridium difficile infection in adult oncology patients. Supportive Care in Cancer, 2015, 23, 1569-1577.	1.0	50
43	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2â€“SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research, 2015, 21, 5131-5138.	3.2	122
44	Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 355-371.	2.0	28
45	A Phase I Study of <i>UGT1A1</i> * <i>28</i> * <i>6</i> Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology, 2015, 88, 164-172.	0.9	19
46	Colon Polyps and the Prevention of Colorectal Cancer. , 2015, , .		3
47	A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Supportive Care in Cancer, 2015, 23, 661-670.	1.0	14
48	Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. Anti-Cancer Drugs, 2015, 26, 35-45.	0.7	17
49	Diarrhoea in the critically ill. Current Opinion in Critical Care, 2015, 21, 142-153.	1.6	54
50	Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics. Current Oncology Reports, 2015, 17, 50.	1.8	59
51	Structure and Inhibition of Microbiome β -Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chemistry and Biology, 2015, 22, 1238-1249.	6.2	203
52	Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Investigational New Drugs, 2015, 33, 1263-1266.	1.2	5
53	Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy. Journal of Controlled Release, 2015, 220, 175-179.	4.8	73
54	Case 31-2015. New England Journal of Medicine, 2015, 373, 1458-1467.	13.9	4
55	Imaging of Fluid in Cancer Patients Treated With Systemic Therapy: Chemotherapy, Molecular Targeted Therapy, and Hematopoietic Stem Cell Transplantation. American Journal of Roentgenology, 2015, 205, 709-719.	1.0	8
56	Interleukinâ€“18 as a target for modulation of irinotecanâ€“induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Limaâ€“Junior <i>et al</i> ., Br J Pharmacol 171: 2335â€“2350. British Journal of Pharmacology, 2015, 172, 4779-4781.	2.7	2
57	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 2015, 41, 646-652.	3.4	53
59	Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Frontiers in Pharmacology, 2016, 7, 414.	1.6	150

#	ARTICLE	IF	CITATIONS
60	Curcumin Inhibits 5-Fluorouracil-Induced Upregulation of CXCL1 and CXCL2 of the Colon Associated with Attenuation of Diarrhoea Development. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 540-547.	1.2	11
61	Effect of Diversion Ileostomy on the Occurrence and Consequences of Chemotherapy-Induced Diarrhea. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 194-200.	0.7	18
62	Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 881-893.	1.1	113
63	Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 507-534.	0.3	2
64	Effect of hesperidin on the pharmacokinetics of CPT11 and its active metabolite SN38 by regulating hepatic Mrp2 in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 421-432.	1.1	10
65	Curcuminoids from <i>Curcuma longa</i> L. reduced intestinal mucositis induced by 5-fluorouracil in mice: Bioadhesive, proliferative, anti-inflammatory and antioxidant effects. <i>Toxicology Reports</i> , 2016, 3, 55-62.	1.6	29
66	Nintedanib in advanced NSCLC: management of adverse events. <i>Lung Cancer Management</i> , 2016, 5, 29-41.	1.5	9
67	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. <i>JAMA Oncology</i> , 2016, 2, 529.	3.4	26
68	The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. <i>Nature Reviews Microbiology</i> , 2016, 14, 273-287.	13.6	552
69	Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 209-227.	12.5	177
70	A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 37-48.	2.0	27
71	Probable Interaction Between Warfarin and Banana Flakes Supplement. <i>Nutrition in Clinical Practice</i> , 2016, 31, 125-131.	1.1	2
72	Gastrointestinal tolerance and plasma status of carotenoids, EPA and DHA with a fiber-enriched tube feed in hospitalized patients initiated on tube nutrition: Randomized controlled trial. <i>Clinical Nutrition</i> , 2017, 36, 380-388.	2.3	12
73	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
75	Impact of chemotherapy on gastrointestinal functions and the enteric nervous system. <i>Maturitas</i> , 2017, 105, 23-29.	1.0	43
76	Real-time imaging of intestinal bacterial β -glucuronidase activity by hydrolysis of a fluorescent probe. <i>Scientific Reports</i> , 2017, 7, 3142.	1.6	30
77	The microbiome and hepatobiliary-pancreatic cancers. <i>Cancer Letters</i> , 2017, 402, 9-15.	3.2	105
78	Sacituzumab govitecan (IMMUGEN132), an anti-Trop2 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. <i>Cancer</i> , 2017, 123, 3843-3854.	2.0	145

#	ARTICLE	IF	CITATIONS
79	Structure-activity relationships of flavonoids as natural inhibitors against E.Âcoli Î²-glucuronidase. Food and Chemical Toxicology, 2017, 109, 975-983.	1.8	42
80	Human microbiome signatures of differential colorectal cancer drug metabolism. Npj Biofilms and Microbiomes, 2017, 3, 27.	2.9	103
81	Systemic anti-cancer therapy-induced diarrhoea. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662	0.2	8
82	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist, 2017, 22, 1039-1048.	1.9	115
83	The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surgical Oncology, 2017, 26, 368-376.	0.8	67
84	Specific Inhibition of Bacterial Î²-Glucuronidase by Pyrazolo[4,3- <i>c</i>]/i>]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity. Journal of Medicinal Chemistry, 2017, 60, 9222-9238.	2.9	30
85	Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Spragueâ€Dawley rats. Cancer Chemotherapy and Pharmacology, 2017, 80, 317-332.	1.1	49
86	Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review. BMJ Open, 2017, 7, e014916.	0.8	6
87	New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin. Chemotherapy, 2017, 62, 62-70.	0.8	34
88	Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics Journal, 2017, 17, 21-28.	0.9	51
89	May cannabinoids prevent the development of chemotherapyâ€induced diarrhea and intestinal mucositis? Experimental study in the rat. Neurogastroenterology and Motility, 2017, 29, e12952.	1.6	29
90	Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review. Clinical Nutrition, 2017, 36, 1465-1472.	2.3	55
91	US oncology-wide incidence, duration, costs and deaths from chemoradiation mucositis and antimucositis therapy benefits. Future Oncology, 2017, 13, 2823-2852.	1.1	23
93	Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development. Biological and Pharmaceutical Bulletin, 2017, 40, 2134-2139.	0.6	10
94	32. Wichtige Infektionen in der gastroenterologischen Onkologie. , 2017, , .		0
95	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Frontiers in Pharmacology, 2017, 8, 354.	1.6	165
96	Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer. Frontiers in Pharmacology, 2017, 8, 603.	1.6	96
97	Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-10.	0.5	19

#	ARTICLE	IF	CITATIONS
98	Pneumatosis cystoides intestinalis associated with sunitinib and a literature review. BMC Cancer, 2017, 17, 732.	1.1	18
99	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 3338-3346.	0.8	69
100	Which Side Effect Related to Chemotherapy Should Be Described to the Patients Before Treatment?. , 2018, , 349-354.		1
101	Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. Gynecologic Oncology, 2018, 150, 173-179.	0.6	19
102	Targeting p53-dependent stem cell loss for intestinal chemoprotection. Science Translational Medicine, 2018, 10, .	5.8	41
103	Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. Future Science OA, 2018, 4, FSO306.	0.9	26
104	Pharmacomicrobiomics: a novel route towards personalized medicine?. Protein and Cell, 2018, 9, 432-445.	4.8	128
105	Clinical Characteristics and Outcomes of Hematologic Malignancy Patients With Positive Clostridium difficile Toxin Immunoassay Versus Polymerase Chain Reaction Test Results. Infection Control and Hospital Epidemiology, 2018, 39, 863-866.	1.0	9
106	Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-associated Diarrhea: A Phase 2a Multicenter Clinical Trial. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 210-218.	0.6	30
107	Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 26-33.	1.3	15
108	Contribution of oxidative stress in acute intestinal mucositis induced by 5 fluorouracil (5-FU) and its pro-drug capecitabine in rats. Toxicology Mechanisms and Methods, 2018, 28, 262-267.	1.3	30
109	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget, 2018, 9, 28989-29006.	0.8	169
110	Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. Oncotarget, 2018, 9, 27958-27973.	0.8	11
111	Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea.. , 2018, 08, .		0
112	Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective. Frontiers in Pharmacology, 2018, 9, 1442.	1.6	38
113	Antineoplastic Agents. , 2018, , 219-232.		0
114	The Role of Bile Acid Sequestrant in Diarrhea Management: Too Good to Be True?. Journal of Clinical Gastroenterology and Hepatology, 2018, 02, .	0.2	2
115	Validation of the Spanish version of the Cancer Symptom Scale in Hispanic cancer patients. International Journal of Nursing Practice, 2018, 24, e12700.	0.8	3

#	ARTICLE	IF	CITATIONS
116	Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon. <i>Journal of Histochemistry and Cytochemistry</i> , 2018, 66, 723-736.	1.3	11
117	TRPV4 Channel Signaling in Macrophages Promotes Gastrointestinal Motility via Direct Effects on Smooth Muscle Cells. <i>Immunity</i> , 2018, 49, 107-119.e4.	6.6	63
118	Diarrhea after autologous stem cell transplantation in low-middle income countries: is <i>Clostridium difficile</i> the most prevalent infectious etiology?. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 105-106.	0.1	0
119	Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 910-916.	2.5	41
120	Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis. <i>Integrative Cancer Therapies</i> , 2018, 17, 1027-1047.	0.8	88
121	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. <i>Journal of Cancer</i> , 2018, 9, 1614-1622.	1.2	17
122	Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients. <i>Seminars in Oncology Nursing</i> , 2018, 34, 227-240.	0.7	17
123	Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery. <i>Journal of Drug Assessment</i> , 2018, 7, 28-33.	1.1	5
124	Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. <i>PLoS ONE</i> , 2018, 13, e0198359.	1.1	33
125	Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 613-622.	0.5	5
126	SN-38-Loaded PLGA microspheres injected intratumorally for cancer: preparation, characterization and evaluation. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101178.	1.4	5
127	Oligomeric Enteral Nutrition in Undernutrition, due to Oncology Treatment-Related Diarrhea. Systematic Review and Proposal of An Algorithm of Action. <i>Nutrients</i> , 2019, 11, 1888.	1.7	18
128	Selenium nanoparticles act as an intestinal p53 inhibitor mitigating chemotherapy-induced diarrhea in mice. <i>Pharmacological Research</i> , 2019, 149, 104475.	3.1	10
129	Neutropenic Sepsis. , 2019, , 1383-1398.		0
130	Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. <i>MAbs</i> , 2019, 11, 987-995.	2.6	74
131	Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz252.	0.4	23
132	Gut microbial modulation in the treatment of chemotherapy-induced diarrhea with Shenzhu Capsule. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 126.	3.7	22
133	Symptom Clusters in Patients With Gastrointestinal Cancers Using Different Dimensions of the Symptom Experience. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 224-234.	0.6	30

#	ARTICLE	IF	CITATIONS
134	Effects of Drugs and Excipients on Hydration Status. <i>Nutrients</i> , 2019, 11, 669.	1.7	22
135	Herbal Medicines for Irinotecan-Induced Diarrhea. <i>Frontiers in Pharmacology</i> , 2019, 10, 182.	1.6	20
136	An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 441-446.	1.1	3
137	Gliclazide Prevents 5-FU-Induced Oral Mucositis by Reducing Oxidative Stress, Inflammation, and P-Selectin Adhesion Molecules. <i>Frontiers in Physiology</i> , 2019, 10, 327.	1.3	18
138	Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 317-328.	2.3	49
139	Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 583-593.	2.6	22
140	An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know. <i>Abdominal Radiology</i> , 2019, 44, 2182-2195.	1.0	2
141	A Citrulline-Based Translational Population System Toxicology Model for Gastrointestinal-Related Adverse Events Associated With Anticancer Treatments. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 951-961.	1.3	2
142	Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide. <i>BMJ Case Reports</i> , 2019, 12, e231544.	0.2	3
143	Inhibition of human carboxylesterases by ginsenosides: structure-activity relationships and inhibitory mechanism. <i>Chinese Medicine</i> , 2019, 14, 56.	1.6	10
144	Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 157-166.	5.7	30
145	Serotonin 3 receptor signaling regulates 5-fluorouracil-mediated apoptosis indirectly via TNF production by enhancing serotonin release from enterochromaffin cells. <i>FASEB Journal</i> , 2019, 33, 1669-1680.	0.2	8
146	Pharmacological inhibition of bacterial Î²-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. <i>Pharmacological Research</i> , 2019, 139, 41-49.	3.1	57
147	Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 169-178.	1.1	12
148	Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries. <i>Medicinal Research Reviews</i> , 2019, 39, 1294-1337.	5.0	32
149	Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea. <i>Toxicological Sciences</i> , 2019, 168, 3-17.	1.4	33
150	Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 531-543.	1.1	13
151	Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death. <i>Biochemical Pharmacology</i> , 2019, 162, 41-54.	2.0	21

#	ARTICLE	IF	CITATIONS
152	The management of neuroendocrine tumours: A nutritional viewpoint. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1046-1057.	5.4	40
153	Practice insights on patient care management overview for chemoradiation toxic mucositis guidelines, guideline-supported therapies and high potency polymerized cross-linked sucralfate (ProThelial). <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 409-422.	0.5	5
154	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 905-927.	2.9	34
155	Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab) Tj ETQq1 1 0.784314 rgBT #Overloc	1.0	13
156	An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101691.	1.0	13
157	Irinotecan Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4919.	1.8	107
158	A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting. <i>Artificial Intelligence in Medicine</i> , 2020, 109, 101925.	3.8	4
159	Precision medicine in drug safety. <i>Current Opinion in Toxicology</i> , 2020, 23-24, 87-97.	2.6	2
160	The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 629-638.	1.1	3
161	Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2020, 43, 1255-1266.	1.4	5
162	Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors. <i>Cancer Research</i> , 2020, 80, 4258-4265.	0.4	9
163	Gastrointestinal side effects of cancer treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097035.	1.1	41
164	Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 599073.	1.3	21
165	Gut Microbiome in Microbial Pathogenicity. , 2020, , 1-36.		0
166	The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9239.	1.8	29
167	Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea. <i>BMC Gastroenterology</i> , 2020, 20, 355.	0.8	5
168	Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2020, 21, 370.	0.7	8
169	The central role of gut microbiota in drug metabolism and personalized medicine. <i>Future Medicinal Chemistry</i> , 2020, 12, 1197-1200.	1.1	11

#	ARTICLE	IF	CITATIONS
170	Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability. <i>Pharmacotherapy</i> , 2020, 40, 704-712.	1.2	14
171	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092849.	0.8	35
172	Pharmacogenomics in Precision Medicine. , 2020, , .		1
173	Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. <i>Frontiers in Pharmacology</i> , 2020, 11, 252.	1.6	16
174	Targeted inhibition of gut bacterial Î²-glucuronidase activity enhances anticancer drug efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7374-7381.	3.3	121
175	Healthcare associated diarrhea, not <i>Clostridioides difficile</i> . <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 319-326.	1.3	1
176	Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs. <i>Toxicology in Vitro</i> , 2020, 68, 104928.	1.1	17
177	Relationship Between the Gut Microbiome and Systemic Chemotherapy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 874-884.	1.1	35
178	Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties. <i>British Journal of Pharmacology</i> , 2020, 177, 2393-2408.	2.7	87
179	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	1.4	57
180	Chemotherapy-induced diarrhoea in dogs and its management with smectite: Results of a monocentric open-label randomized clinical trial. <i>Veterinary and Comparative Oncology</i> , 2021, 19, 25-33.	0.8	5
181	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 237-255.	1.1	14
182	Effects of 10.6-Î¼m laser moxibustion and electroacupuncture at ST36 in a 5-Fu-induced diarrhea rat model. <i>Supportive Care in Cancer</i> , 2021, 29, 2561-2569.	1.0	3
183	Effects of mild moxibustion on intestinal microbiome and NLRP3 inflammasome in rats with 5-fluorouracil-induced intestinal mucositis. <i>Journal of Integrative Medicine</i> , 2021, 19, 144-157.	1.4	14
184	Distinct diarrhea profiles during outpatient chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 2363-2373.	1.0	10
185	Predisposing factors and clinical impact of high-output syndrome after sphincter-preserving surgery with covering ileostomy for rectal cancer: a retrospective single-center cohort study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 118-125.	1.0	2
186	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
187	Quality of life of patients with cancer undergoing chemotherapy in hospitals in Belo Horizonte, Minas Gerais State, Brazil: does individual characteristics matter?. <i>Cadernos De Saude Publica</i> , 2021, 37, e00002220.	0.4	2

#	ARTICLE	IF	CITATIONS
188	A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction. JMIR MHealth and UHealth, 2021, 9, e27024.	1.8	5
189	Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines, 2021, 9, 189.	1.4	24
190	Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction – A case report. International Journal of Surgery Case Reports, 2021, 79, 131-134.	0.2	5
191	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. European Journal of Cancer, 2021, 144, 351-359.	1.3	2
192	Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case Report. Oncology and Therapy, 2021, 9, 247-253.	1.0	3
193	A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. Journal of Medical Toxicology, 2022, 18, 43-55.	0.8	18
194	Drug Response Diversity: A Hidden Bacterium?. Journal of Personalized Medicine, 2021, 11, 345.	1.1	2
195	Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin. Probiotics and Antimicrobial Proteins, 2022, 14, 60-71.	1.9	14
196	482 Defining drugs that are high-risk associations for drug reactions within the hospital setting. Journal of Investigative Dermatology, 2021, 141, S83.	0.3	0
197	Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. Toxicology Research, 2021, 10, 476-486.	0.9	16
198	The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy. Romanian Journal of Morphology and Embryology, 2021, 61, 1121-1128.	0.4	1
199	Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer Reducing E. coli Adherence and β -Glucuronidase Activity. Cancers, 2021, 13, 2952.	1.7	19
200	RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics. Frontiers in Nanotechnology, 2021, 3, .	2.4	17
201	Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection. Pharmacogenomics Journal, 2021, 21, 673-681.	0.9	14
202	Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice. Brain, Behavior, and Immunity, 2021, 95, 401-412.	2.0	55
203	Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. Microorganisms, 2021, 9, 1469.	1.6	6
204	β -Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Frontiers in Pharmacology, 2021, 12, 689491.	1.6	10
205	DARK Classics in Chemical Neuroscience: Loperamide. ACS Chemical Neuroscience, 2021, 12, 2964-2973.	1.7	2

#	ARTICLE	IF	CITATIONS
206	Human gut bacterial β -glucuronidase inhibition: An emerging approach to manage medication therapy. <i>Biochemical Pharmacology</i> , 2021, 190, 114566.	2.0	23
207	Recent advances in trophoblast cell surface antigen 2 targeted therapy for solid tumors. <i>Drug Development Research</i> , 2021, 82, 1096-1110.	1.4	15
208	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4277.	1.0	6
209	Gut Microbiome and Drug Metabolism. <i>Biomedical Chemistry Research and Methods</i> , 2021, 4, e00146.	0.1	1
210	<i>Plectranthus amboinicus</i> (Spreng.) Semi-purified Fractions with Selective β -Glucuronidase Inhibition Elucidated with gas chromatography-mass spectrometry and in silico docking. <i>Pharmacognosy Magazine</i> , 2021, 17, 268.	0.3	0
211	Colonoscopy. , 2015, , 41-112.		1
212	Pharmacomicrobiomics. , 2020, , 181-199.		1
213	Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. <i>JCI Insight</i> , 2019, 4, .	2.3	34
214	Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs of Today</i> , 2019, 55, 575.	0.7	30
215	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016, 29, 127-36.	0.4	8
216	Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan TM 's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. <i>Current Cancer Drug Targets</i> , 2019, 19, 551-560.	0.8	8
217	Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization. <i>Current Cancer Drug Targets</i> , 2020, 20, 130-145.	0.8	55
218	Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 842-874.	0.9	19
219	Mitigation of Radiation-induced Gastrointestinal System Injury using Resveratrol or Alpha-lipoic Acid: A Pilot Histopathological Study. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2020, 19, 413-424.	1.1	14
220	A High Throughput Assay for Discovery of Bacterial β -Glucuronidase Inhibitors. <i>Current Chemical Genomics</i> , 2011, 5, 13-20.	2.0	19
221	Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects. <i>International Journal of Clinical Medicine</i> , 2014, 05, 393-406.	0.1	50
222	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 418-31.	0.2	48
223	Treatment Toxicity. <i>UNIPA Springer Series</i> , 2021, , 291-308.	0.1	0

#	ARTICLE	IF	CITATIONS
224	Review article: drug-induced small bowel injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1370-1388.	1.9	12
225	Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?. <i>Cancers</i> , 2021, 13, 5346.	1.7	11
226	Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model. <i>Drug Metabolism and Disposition</i> , 2022, 50, 33-42.	1.7	3
227	Ciddi metabolik asidoz sonras saalkalim: (pH=6.66). <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2014, , 64-6.	0.1	0
228	Neutropenic Sepsis. , 2018, , 1-16.		0
229	Chemotherapy Induced Diarrhea: A Case Report. <i>Journal of Cancer Prevention & Current Research</i> , 2018, 9, .	0.1	1
230	Merit-based Claim Adjudication for Cancer Treatment Toxicities – Policy Trends that Lower Downstream Costs. <i>Journal of Insurance Medicine (New York, N Y)</i> , 2018, 47, 236-248.	0.1	0
231	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
232	Gastrointestinal Complications of Chemotherapy. , 2020, , 29-50.		0
233	Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, e22938.	1.4	24
234	Protective Effects of Naringin on Lung Toxicity Induced by 5-Fluorouracil in Rats. <i>Kocatepe Veteriner Dergisi</i> , 0, , .	0.2	0
235	Carboxylesterase 2: A Key Enzyme in Drug and Prodrug Metabolism. <i>Juntendo Medical Journal</i> , 2020, 66, 120-124.	0.1	1
237	Exploring the Relationship between Diarrhea and Fatigue that can occur during Cancer Treatment: Using Structural Equation Modeling. <i>Puerto Rico Health Sciences Journal</i> , 2019, 38, 81-86.	0.2	1
239	Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records. <i>European Journal of Oncology Nursing</i> , 2022, 56, 102066.	0.9	13
240	Pharmacogenomics of Anti-Cancer Drugs. , 2021, , .		0
241	Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1021.	1.8	6
242	<i>Bifidobacterium longum</i> subsp. <i>longum</i> 51A attenuates intestinal injury against irinotecan-induced mucositis in mice. <i>Life Sciences</i> , 2022, 289, 120243.	2.0	14
243	Chemotherapy induced gastrointestinal toxicities. <i>Advances in Cancer Research</i> , 2022, , 131-166.	1.9	24

#	ARTICLE	IF	CITATIONS
244	Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 5-26.	1.5	4
245	Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. <i>Pancreatology</i> , 2022, 22, 258-263.	0.5	1
246	Therapeutic possibilities of selected gastrointestinal complications in oncology patients. <i>Onkologie (Czech Republic)</i> , 2022, 16, 91-94.	0.0	0
247	Role of probiotics in the management of cervical cancer: An update. <i>Clinical Nutrition ESPEN</i> , 2022, 48, 5-16.	0.5	9
248	Drug-induced diarrhea associated with antineoplastic drugs. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 5-18.	0.1	0
249	Assessment of the incidence and etiology of nosocomial diarrhea in a medical ward in Iraq. <i>Journal of Medicine and Life</i> , 2022, 15, 132-137.	0.4	1
250	KDR genetic predictor of toxicities induced by sorafenib and regorafenib. <i>Pharmacogenomics Journal</i> , 2022, 22, 251-257.	0.9	2
251	Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 2112.	1.7	11
252	Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5332.	1.8	6
254	Protective Effects of Oxyberberine in 5-Fluorouracil-Induced Intestinal Mucositis in the Mice Model. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-15.	0.5	4
255	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
256	Scutellaria baicalensis and its constituents baicalin and baicalein as antidotes or protective agents against chemical toxicities: a comprehensive review. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 1297-1329.	1.4	10
258	Recent Progress on Strategies and Applications of Imaging for Intestinal Microflora. <i>Chinese Journal of Organic Chemistry</i> , 2022, 42, 1375.	0.6	0
259	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
260	Monitoring energy balance through clinical and serum biomarkers in patients with hematologic malignancies undergoing chemotherapy. <i>Annals of Hematology</i> , 2022, 101, 2759-2769.	0.8	1
261	Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicants. <i>Archives of Toxicology</i> , 2023, 97, 235-254.	1.9	7
262	Natural product inspired leads in the discovery of anticancer agents: an update. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 8605-8628.	2.0	5
264	Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF- κ B Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	6

#	ARTICLE	IF	CITATIONS
265	Biosynthetic Silver Nanoparticles Inhibit the Malignant Behavior of Gastric Cancer Cells and Enhance the Therapeutic Effect of 5-Fluorouracil by Promoting Intracellular ROS Generation and Apoptosis. <i>Pharmaceutics</i> , 2022, 14, 2109.	2.0	6
267	HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 571-581.	1.1	5
268	Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. <i>Supportive Care in Cancer</i> , 2022, 30, 10471-10482.	1.0	3
269	Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. <i>Breast</i> , 2022, 66, 169-177.	0.9	27
270	Vitamin A Ameliorated Irinotecan-Induced Diarrhea in a Piglet Model Involving Enteric Glia Modulation and Immune Cells Infiltration. <i>Nutrients</i> , 2022, 14, 5120.	1.7	1
271	Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
273	Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology. <i>Chinese Medicine</i> , 2022, 17, .	1.6	3
274	Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan. <i>Current Drug Metabolism</i> , 2022, 23, 1000-1010.	0.7	2
275	Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211443.	0.8	5
276	Could paraprobiotics be a safer alternative to probiotics for managing cancer chemotherapy-induced gastrointestinal toxicities?. <i>Brazilian Journal of Medical and Biological Research</i> , 0, 55, .	0.7	3
277	Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More. <i>Current Oncology</i> , 2023, 30, 908-922.	0.9	2
278	Anti-Colorectal Cancer Effects of a Novel Camptothecin Derivative PCC0208037 In Vitro and In Vivo. <i>Pharmaceutics</i> , 2023, 16, 53.	1.7	1
279	Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
280	Epigenetics of radiation-induced GI damage: Role of protein modifications. , 2023, , 545-563.		0
281	Selenium nanoparticles: Properties, preparation methods, and therapeutic applications. <i>Chemico-Biological Interactions</i> , 2023, 378, 110483.	1.7	9
282	Management of Side Effects in Pediatric Cancer Management. , 2022, , 1-14.		0
283	Chemotherapy: how to reduce its adverse effects while maintaining the potency?. , 2023, 40, .		23
284	The Association between Dietary Patterns and Chemotherapy Side Effects in Patients with Breast Cancer (BrCa). <i>Nutrition and Cancer</i> , 2023, 75, 948-959.	0.9	1

#	ARTICLE	IF	CITATIONS
286	Acquired Disorders of Hypomagnesemia. Mayo Clinic Proceedings, 2023, 98, 581-596.	1.4	5
287	Interactions Between Antidepressants and Intestinal Microbiota. Neurotherapeutics, 2023, 20, 359-371.	2.1	1
288	Onconeurology: acute kidney disease after preventive ileostomy in a patient with colorectal cancer. Nephrology (Saint-Petersburg), 2023, 27, 102-107.	0.1	0
289	Recent advances in SN-38 drug delivery system. International Journal of Pharmaceutics, 2023, 637, 122886.	2.6	4
290	Gastrointestinal Side Effects of Anticancer Therapy. , 2023, , 1-36.		0
291	<sc>CDK4</sc> /6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapy-induced diarrhea. Journal of Pathology, 0, , .	2.1	1
297	Abdomen and pelvis: Symptoms and toxicities. , 2024, , 367-378.		0
300	LEVERAGING SMALL MOLECULES TO MODULATE THE MICROBIOME TO TREAT HUMAN DISEASES. Medicinal Chemistry Reviews, 0, , 389-414.	0.1	0
303	Leaving No Stone Unturned: Unraveling the Path to Maximizing the Potential for Discovery of Novel Antineoplastics. , 2023, , 81-102.		0
307	Non-surgical Cancer Treatments. , 2023, , 131-147.		0
311	Utilization of the microbiome in personalized medicine. Nature Reviews Microbiology, 0, , .	13.6	5
315	Principles of Xenobiotic Metabolism (Biotransformation). , 2023, , 13-33.		0